SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule

Alexis Wérion, Leïla Belkhir, Marie Perrot, +53

Kidney International

GlomerulonephritisUrologyRenal FunctionMedicineKidney Failure +8

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Franck Morschhauser, Steven Le Gouill, Pierre Feugier, +17

The Lancet Haematology

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyImmunotherapy +2

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Éric Van Den Neste, Marc André, Thomas Gastinne, +17

Haematologica

ImmunologyPathologyPhase Ii StudyClassical Hodgkin LymphomaPharmacotherapy +18

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Vincent Camus, Cédric Rossi, Pierre Sesques, +28

Blood Advances

Reconstructing Mayaro virus circulation in French Guiana shows frequent spillovers

Nathanaël Hozé, Henrik Salje, Dominique Rousset, +8

Nature Communications

Impact of Zika Virus Emergence in French Guiana: A Large General Population Seroprevalence Survey

Claude Flamand, Sarah Bailly, Camille Fritzell, +14

The Journal of Infectious Diseases

Spatial Distribution and Burden of Emerging Arboviruses in French Guiana

Sarah Bailly, Dominique Rousset, Camille Fritzell, +14

Viruses

Virus EpidemiologyViral DiagnosticsImmunodeficienciesVirus TransmissionArbovirus +16

COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes

Raphaël Lattenist, Julien De Greef, Sarah Bailly, +1

Indian Journal of Hematology and Blood Transfusion

Hematological DiseaseLong CovidAdult PatientsCovid-19 PandemicClinical Epidemiology +6

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, +18

EClinicalMedicine

Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020

Claude Flamand, Christelle Alves Sarmento, Antoine Enfissi, +18

PLoS neglected tropical diseases